Insider Trades
Supernus CEO Jack Khattar Ends Up With 3,413,555 Shares After Merger Swap
Khattar's old Supernus shares converted at 1.5401 Indivior shares each, and Indivior took the Supernus name, his filing shows.
Supernus (SUPN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Insider Trades
Khattar's old Supernus shares converted at 1.5401 Indivior shares each, and Indivior took the Supernus name, his filing shows.
Insider Trades
Jack Khattar's directly and trust-held shares were converted at 1.5401 Indivior shares apiece, with no cash beyond fractional shares.
Earnings
The special dividend triggers the adjustment, which sets a conversion price of about $32.33 per share, the company said.
Deals
Holders got 1.5401 Indivior shares per Supernus share, and former Indivior holders own about 56.5% of the combined company.
Deals
The merged drugmaker, led by CEO Jack Khattar, funded the $1.0 billion payout with a $650 million Citibank loan and cash on hand.
Earnings
Onapgo net sales reached $17.1 million in the third quarter, and Jack Khattar says supply problems are now behind the Parkinson's drug.
SEC Filings
The cash payout is reserved for Indivior holders of record on October 30, funded partly by a $650 million term loan.
SEC Filings
A temporary conversion right tied to the dividend flipped the notes to a current liability and left a $501 million working capital deficit.
Deals
Sublocade sales rose 22% to $267 million and operating costs fell, in the drugmaker's last quarter as a standalone company.
Deals
The drugmaker ended an undrawn, uncommitted revolving line and released the bank's hold on collateral, with a new secured facility planned at closing.
SEC Filings
The company also filed for a second Onapgo supplier and still expects potential FDA approval of it by mid-year 2027.
Earnings
The drugmaker will hold a 4:30 p.m. ET call with its CEO and CFO, and a webcast replay will stay up for 60 days.